CRISPR prime editing used inside the human body for the first time, in a Wilson disease patient

Prime Medicine gave the first patient in a phase 1/2 trial for Wilson disease, which damages the liver and nerves, a single intravenous infusion of a prime-editing therapy; Nature reports it as the first in-body use of the technique. Whether the edit worked is not yet known; first data are expected in 2027.